ReviewMolecular biomedicine2025
Cancer pain: molecular mechanisms and management.
Review in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Tramadol induced hypoxia signaling and paraptosis-like cell death in breast cancer cells via HIF-1α and ATF4 dependent pathways.Redox report : communications in free radical research · 2026Article
- Cancer pain.Nature reviews. Disease primers · 2026Review
- Multimodal Management of Pain in Oral Squamous Cell Carcinoma: A Mechanism-Based Approach.Current pain and headache reports · 2026Review
- A prospective multimethod investigation of cancer-related pain integrating clinical data and machine learning: results from the RUGGI Study.Journal of anesthesia, analgesia and critical care · 2026Article
- Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review.Current treatment options in oncology · 2026Review
- Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026Review
- The Kv4.3 channel on c-low threshold mechanoreceptors in DRG is a key mediator transforming tactile stimuli into nociceptive signals in chemotherapy-induced neuropathy.Acta pharmaceutica Sinica. B · 2026Article
- Review
- Pharmacological Mechanisms and Clinical Applications of Oxycodone in Cancer Pain Management: A Narrative Review.Drug design, development and therapy · 2026Review
- Transcriptomic Association of COL3A1Pain research & management · 2026Article
- Research progress on chemical composition, pharmacological effects, clinical applications, and processing ofFrontiers in pharmacology · 2026Review
- Comparative Effectiveness of Mind-Body Exercise Modalities on Pain Intensity and Fatigue in Patients with Non-Neuropathic Cancer-Related Pain: A Systematic Review and Network Meta-Analysis.Journal of pain research · 2026Review
- Behavioral assessment of pain in rodents: advances from evoked responses to spontaneous states and multimodal approaches.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Pharmacological Management of Cancer Pain: Advances in Treatment Strategies and Drug Delivery Systems.Pharmaceutics · 2025Review
- Transcriptomic Differences Related to Neck Pain in Patients with Oropharyngeal Squamous Cell Carcinoma.Genes · 2025Article
- Understanding Cancer-Related Pain: Pathophysiology, Classification, and Treatment Modalities.Cureus · 2025Review
- The Relationship Between Radiotherapy-Induced Pain Response Score and Pain Biomarkers TRPV1, β-Endorphin (bEP), Neurotensin (NT), and Orexin A (OXA) in Patients with Bone Metastases.Life (Basel, Switzerland) · 2025Article
- Virtual Reality and Digital Interventions in Cancer Pain Relief: A New Frontier in Supportive Oncology Care.Journal of mid-life healthReview
- Targeting Neuropilin-1 for Cancer Pain Treatment: A Trial With Potential for Clinical Translation.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer pain, a highly prevalent and distressing symptom among cancer patients, has a seriously harmful effect on their life and presents a complex challenge in clinical management. Despite extensive research efforts and the existence of clinical guidelines, significant controversies persist regarding the molecular mechanisms underpinning cancer pain as well as the most effective management strategies. This review systematically delves into the neurobiological underpinnings of cancer pain, centering on the interplay of peripheral and central sensitization, cellular stress and dysfunction, as well as the crucial roles of various signaling pathways and epigenetic regulation in its pathogenesis. In terms of treatment, the fundamental strategy involves a comprehensive initial assessment of cancer pain, followed by targeted interventions based on the assessment findings. It advocates for a multimodal approach that integrates pharmacological with non-pharmacological therapies. However, ongoing debates surround issues related to opioid rotation protocols and the long-term safety of opioid use. Furthermore, it underscores the underexplored potential of personalized therapies targeting molecular pathways and the need for standardized, interdisciplinary pain assessment tools. By bridging mechanistic research and clinical practice, this work potentially provides a framework for refining guideline implementation, advancing targeted therapies, and improving patient-centered care, thereby contributing to the evolution of precision oncology and holistic pain management paradigms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.